{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:43:06Z","timestamp":1791999786181,"version":"4.4.0"},"reference-count":254,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40257-020-00534-y","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T20:03:18Z","timestamp":1593547398000},"page":"601-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Emerging Therapeutic Options for Chronic Pruritus"],"prefix":"10.1007","volume":"21","author":[{"given":"Radomir","family":"Reszke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"534_CR1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","volume":"87","author":"S St\u00e4nder","year":"2007","unstructured":"St\u00e4nder S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87:291\u20134.","journal-title":"Acta Derm Venereol."},{"key":"534_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2340\/00015555-3164","volume":"99","author":"E Weisshaar","year":"2019","unstructured":"Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99:469\u2013506. https:\/\/doi.org\/10.2340\/00015555-3164.","journal-title":"Acta Derm Venereol."},{"key":"534_CR3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1468-3083.2008.02591.x","volume":"22","author":"B Amatya","year":"2008","unstructured":"Amatya B, Wennersten G, Nordlind K. Patients\u2019 perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22:822\u20136.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jid.2019.05.034","volume":"140","author":"FJ Dalgard","year":"2020","unstructured":"Dalgard FJ, Svensson \u00c5, Halvorsen JA, et al. Itch and mental health in dermatological patients across Europe: a cross-sectional study in 13 countries. J Investig Dermatol. 2020;140:568\u201373.","journal-title":"J Investig Dermatol."},{"key":"534_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5114\/ada.2018.80271","volume":"36","author":"D Dimitrov","year":"2019","unstructured":"Dimitrov D, Matusiak \u0141, Szepietowski JC. Stigmatization in Arabic psoriatic patients in the United Arab Emirates\u2014a cross sectional study. Postepy Dermatol Alergol. 2019;36:425\u201330.","journal-title":"Postepy Dermatol Alergol."},{"key":"534_CR6","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","volume":"142","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142:1375\u201390. https:\/\/doi.org\/10.1016\/j.jaci.2018.09.005.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/jdv.15973","volume":"34","author":"G Yosipovitch","year":"2020","unstructured":"Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34:239\u201350. https:\/\/doi.org\/10.1111\/jdv.15973.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e3182662098","volume":"79","author":"EE Benarroch","year":"2012","unstructured":"Benarroch EE. Endogenous opioid systems: current concepts and clinical correlations. Neurology. 2012;79:807\u201314.","journal-title":"Neurology."},{"key":"534_CR9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/awm255","volume":"131","author":"G Henriksen","year":"2008","unstructured":"Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. Brain. 2008;131:1171\u201396.","journal-title":"Brain."},{"key":"534_CR10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Lotts T, Antal A, et al. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol. 2012;92:555\u201360.","journal-title":"Acta Derm Venereol."},{"key":"534_CR11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2340\/00015555-0650","volume":"89","author":"A Reich","year":"2009","unstructured":"Reich A, St\u00e4nder S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol. 2009;89:236\u201344.","journal-title":"Acta Derm Venereol."},{"key":"534_CR12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/00000542-200003000-00023","volume":"92","author":"MC Ko","year":"2000","unstructured":"Ko MC, Naughton NN. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology. 2000;92:795\u2013805.","journal-title":"Anesthesiology."},{"key":"534_CR13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.103.061101","volume":"310","author":"MC Ko","year":"2004","unstructured":"Ko MC, Song MS, Edwards T, et al. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther. 2004;310:169\u201376.","journal-title":"J Pharmacol Exp Ther."},{"key":"534_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/jpet.108.143925","volume":"328","author":"MC Ko","year":"2009","unstructured":"Ko MC, Husbands SM. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther. 2009;328:193\u2013200.","journal-title":"J Pharmacol Exp Ther."},{"key":"534_CR15","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.jid.5700942","volume":"127","author":"M Tominaga","year":"2007","unstructured":"Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Investig Dermatol. 2007;127:2228\u201335.","journal-title":"J Investig Dermatol."},{"key":"534_CR16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2133.2011.10347.x","volume":"165","author":"K Taneda","year":"2011","unstructured":"Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol. 2011;165:277\u201384.","journal-title":"Br J Dermatol."},{"key":"534_CR17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2340\/00015555-2595","volume":"97","author":"P Kupczyk","year":"2017","unstructured":"Kupczyk P, Reich A, Ho\u0142ysz M, et al. Opioid receptors in psoriatic skin: relationship with itch. Acta Derm Venereol. 2017;97:564\u201370.","journal-title":"Acta Derm Venereol."},{"key":"534_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16360","author":"A Wieczorek","year":"2020","unstructured":"Wieczorek A, Krajewski P, Kozio\u0142-Ga\u0142czy\u0144ska M, et al. Opioid receptors expression in the skin of hemodialysis patients suffering from uremic pruritus. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"534_CR19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","volume":"123","author":"NV Bergasa","year":"1995","unstructured":"Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med. 1995;123:161\u20137.","journal-title":"Ann Intern Med."},{"key":"534_CR20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/BF03018748","volume":"50","author":"T Okutomi","year":"2003","unstructured":"Okutomi T, Saito M, Mochizuki J, et al. Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients. Can J Anaesth. 2003;50:961\u20132.","journal-title":"Can J Anaesth."},{"key":"534_CR21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12664-009-0070-8","volume":"28","author":"GG Joshi","year":"2009","unstructured":"Joshi GG, Thakur BS, Sircar S, et al. Role of intravenous naloxone in severe pruritus of acute cholestasis. Indian J Gastroenterol. 2009;28:180\u20132.","journal-title":"Indian J Gastroenterol."},{"key":"534_CR22","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(96)04176-1","volume":"348","author":"G Peer","year":"1996","unstructured":"Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348:1552\u20134.","journal-title":"Lancet."},{"key":"534_CR23","first-page":"533","volume":"41","author":"D Metze","year":"1999","unstructured":"Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41:533\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s00105-004-0802-8","volume":"55","author":"A Brune","year":"2004","unstructured":"Brune A, Metze D, Luger TA, et al. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Hautarzt. 2004;55:1130\u20136.","journal-title":"Hautarzt."},{"key":"534_CR25","doi-asserted-by":"publisher","first-page":"804296","DOI":"10.1155\/2011\/804296","volume":"2011","author":"T Frech","year":"2011","unstructured":"Frech T, Novak K, Revelo MP, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol. 2011;2011:804296. https:\/\/doi.org\/10.1155\/2011\/804296.","journal-title":"Int J Rheumatol."},{"key":"534_CR26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/0091-6749(88)90571-4","volume":"81","author":"D Banerji","year":"1988","unstructured":"Banerji D, Fox M, Seleznick M, et al. J Allergy Clin Immunol. 1988;81:252.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","volume":"41","author":"NV Bergasa","year":"1999","unstructured":"Bergasa NV, Alling DW, Talbot TL, et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol. 1999;41:431\u20134.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0885-3924(96)00154-6","volume":"12","author":"E Dunteman","year":"1996","unstructured":"Dunteman E, Karanikolas M, Filos KS. Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines. J Pain Symptom Manag. 1996;12:255\u201360.","journal-title":"J Pain Symptom Manag."},{"key":"534_CR29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","volume":"54","author":"AG Dawn","year":"2006","unstructured":"Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol. 2006;54:527\u201331.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1447-0756.1999.tb01149.x","volume":"25","author":"C Somrat","year":"1999","unstructured":"Somrat C, Oranuch K, Ketchada U, et al. Optimal dose of nalbuphine for treatment of intrathecal-morphine induced pruritus after caesarean section. J Obstet Gynaecol Res. 1999;25:209\u201313.","journal-title":"J Obstet Gynaecol Res."},{"key":"534_CR31","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1213\/01.ANE.0000066015.21364.7D","volume":"96","author":"S Charuluxananan","year":"2003","unstructured":"Charuluxananan S, Kyokong O, Somboonviboon W, et al. Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. Anesth Analg. 2003;96:1789\u201393.","journal-title":"Anesth Analg."},{"key":"534_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12882-015-0043-3","volume":"16","author":"A Hawi","year":"2015","unstructured":"Hawi A, Alcorn H Jr, Berg J, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol. 2015;16:47. https:\/\/doi.org\/10.1186\/s12882-015-0043-3.","journal-title":"BMC Nephrol."},{"key":"534_CR33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000484573","volume":"46","author":"VS Mathur","year":"2017","unstructured":"Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine ER tablets for uremic pruritus. Am J Nephrol. 2017;46:450\u20138.","journal-title":"Am J Nephrol."},{"key":"534_CR34","unstructured":"Trevi Therapeutics Ltd. Trevi therapeutics announces positive results from phase 2 trial in Prurigo Nodularis. https:\/\/www.trevitherapeutics.com\/wp-content\/uploads\/2019\/01\/TreviPNToplineDataPR.10_.13_.16_.FINAL_pdf."},{"key":"534_CR35","unstructured":"Trevi Therapeutics Ltd. PRISM study\u2014pruritus relief through itch scratch modulation (PRISM). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03497975."},{"key":"534_CR36","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","volume":"16","author":"B Wikstr\u00f6m","year":"2005","unstructured":"Wikstr\u00f6m B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16:3742\u20137.","journal-title":"J Am Soc Nephrol."},{"key":"534_CR37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a PHASE III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25:1251\u20137.","journal-title":"Nephrol Dial Transplant."},{"key":"534_CR38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","volume":"36","author":"H Kumagai","year":"2012","unstructured":"Kumagai H, Ebata T, Takamori K, et al. Efficacy and safety of a novel \u0138-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol. 2012;36:175\u201383.","journal-title":"Am J Nephrol."},{"key":"534_CR39","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5414\/CP201852","volume":"51","author":"Y Ueno","year":"2013","unstructured":"Ueno Y, Mori A, Yanagita T. One year long-term study on abuse liability of nalfurafine in hemodialysis patients. Int J Clin Pharmacol Ther. 2013;51:823\u201331.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"534_CR40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s41100-017-0133-8","volume":"3","author":"H Nakamoto","year":"2017","unstructured":"Nakamoto H, Oh T, Shimamura N, et al. Nalfurafine hydrochloride for refractory pruritus in peritoneal dialysis patients: a phase III, multi-institutional, non-controlled, open-label trial. Ren Replace Ther. 2017;3:51.","journal-title":"Ren Replace Ther."},{"key":"534_CR41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJNRD.S145720","volume":"11","author":"H Kozono","year":"2018","unstructured":"Kozono H, Yoshitani H, Nakano R. Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch\u00ae capsules 2.5\u00a0\u03bcg) in 3762 hemodialysis patients with intractable pruritus. Int J Nephrol Renovasc Dis. 2018;11:9\u201324.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"534_CR42","doi-asserted-by":"publisher","first-page":"e0178991","DOI":"10.1371\/journal.pone.0178991","volume":"12","author":"K Kamimura","year":"2017","unstructured":"Kamimura K, Yokoo T, Kamimura H, et al. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PLoS One. 2017;12:e0178991. https:\/\/doi.org\/10.1371\/journal.pone.0178991.","journal-title":"PLoS One."},{"key":"534_CR43","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/hepr.12830","volume":"47","author":"H Kumada","year":"2017","unstructured":"Kumada H, Miyakawa H, Muramatsu T, et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol Res. 2017;47:972\u201382.","journal-title":"Hepatol Res."},{"key":"534_CR44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/hepr.13075","volume":"48","author":"N Akuta","year":"2018","unstructured":"Akuta N, Kumada H, Fujiyama S, et al. Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: preliminary prospective confirmatory trial. Hepatol Res. 2018;48:810\u20133.","journal-title":"Hepatol Res."},{"key":"534_CR45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jcpt.12404","volume":"41","author":"A Albert-Vartanian","year":"2016","unstructured":"Albert-Vartanian A, Boyd MR, Hall AL, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016;41:371\u201382.","journal-title":"J Clin Pharm Ther."},{"issue":"5","key":"534_CR46","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ekir.2020.01.006","volume":"5","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Mathur V, Germain MJ, et al. Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney Int Rep. 2020;5(5):600\u201310. https:\/\/doi.org\/10.1016\/j.ekir.2020.01.006.","journal-title":"Kidney Int Rep"},{"key":"534_CR47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","volume":"382","author":"S Fishbane","year":"2020","unstructured":"Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382:222\u201332.","journal-title":"N Engl J Med."},{"key":"534_CR48","unstructured":"Cara Therapeutics, Inc. A study to evaluate the safety and efficacy of CR845 in chronic kidney disease patients with moderate-to-severe pruritus. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03617536."},{"key":"534_CR49","unstructured":"Cara Therapeutics, Inc., Study to evaluate the safety and efficacy of oral CR845 (difelikefalin) in patients with primary biliary cholangitis (PBC) and moderate-to-severe pruritus. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03995212."},{"key":"534_CR50","first-page":"557","volume":"12","author":"T Lotts","year":"2014","unstructured":"Lotts T, St\u00e4nder S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges. 2014;12:557\u20139.","journal-title":"J Dtsch Dermatol Ges."},{"key":"534_CR51","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bjd.18025","volume":"181","author":"S St\u00e4nder","year":"2019","unstructured":"St\u00e4nder S, Yosipovitch G. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. Br J Dermatol. 2019;181:932\u20138.","journal-title":"Br J Dermatol."},{"key":"534_CR52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","volume":"138","author":"LA Nattkemper","year":"2018","unstructured":"Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Investig Dermatol. 2018;138:1311\u20137.","journal-title":"J Investig Dermatol."},{"key":"534_CR53","unstructured":"US FDA. Emend prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/207865lbl.pdf."},{"key":"534_CR54","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMc0906670","volume":"361","author":"A Duval","year":"2009","unstructured":"Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med. 2009;361:1415\u20136.","journal-title":"N Engl J Med."},{"key":"534_CR55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","volume":"363","author":"B Vincenzi","year":"2010","unstructured":"Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363:397\u20138.","journal-title":"N Engl J Med."},{"key":"534_CR56","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00520-010-0895-9","volume":"18","author":"B Vincenzi","year":"2010","unstructured":"Vincenzi B, Fratto ME, Santini D, et al. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer. 2010;18:1229\u201330.","journal-title":"Support Care Cancer."},{"key":"534_CR57","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","volume":"13","author":"D Santini","year":"2012","unstructured":"Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13:1020\u20134.","journal-title":"Lancet Oncol."},{"key":"534_CR58","doi-asserted-by":"publisher","first-page":"e10968","DOI":"10.1371\/journal.pone.0010968","volume":"5","author":"S St\u00e4nder","year":"2010","unstructured":"St\u00e4nder S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5:e10968. https:\/\/doi.org\/10.1371\/journal.pone.0010968.","journal-title":"PLoS One."},{"key":"534_CR59","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/jdv.15905","volume":"33","author":"K Agelopoulos","year":"2019","unstructured":"Agelopoulos K, R\u00fclander F, Dangelmaier J, et al. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1\/2 activation. J Eur Acad Dermatol Venereol. 2019;33:2371\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"882\u201391","key":"534_CR60","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.jaad.2018.02.030","volume":"78","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, St\u00e4nder S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol. 2018;78(882\u201391):e10. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.030.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR61","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","volume":"80","author":"S St\u00e4nder","year":"2019","unstructured":"St\u00e4nder S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019;80:1395\u2013402.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR62","unstructured":"Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin. http:\/\/ir.menlotherapeutics.com\/news-releases\/news-release-details\/menlo-therapeutics-announces-results-phase-2-trial-serlopitant-0."},{"key":"534_CR63","unstructured":"Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis. http:\/\/ir.menlotherapeutics.com\/news-releases\/news-release-details\/menlo-therapeutics-announces-results-two-phase-3-clinical-trials."},{"key":"534_CR64","unstructured":"Menlon Therapeutics Inc., Study of the efficacy, safety, and tolerability of serlopitant for pruritus (itch) in atopic dermatitis (ATOMIK). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02975206."},{"key":"534_CR65","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jaad.2020.01.056","volume":"82","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Bagel J, Lebwohl M, et al. Serlopitant for psoriatic pruritus: a phase 2 randomized, double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2020;82:1314\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.056.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR66","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jaad.2019.09.014","volume":"82","author":"AS Chiou","year":"2020","unstructured":"Chiou AS, Choi S, Barriga M, et al. Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: a randomized clinical trial. J Am Acad Dermatol. 2020;82:1415\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.014.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR67","unstructured":"Stanford University. A neurokinin-1 receptor antagonist for the treatment of pruritus in patients with epidermolysis bullosa. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03836001."},{"key":"534_CR68","first-page":"AB300","volume":"79","author":"A Heitman","year":"2018","unstructured":"Heitman A, Xiao C, Cho Y, et al. Tradipitant improves worst itch and disease severity in patients with chronic pruritus related to atopic dermatitis. J Am Acad Dermatol. 2018;79:AB300.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR69","unstructured":"Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis. https:\/\/vandapharmaceuticalsinc.gcs-web.com\/node\/13961\/pdf."},{"key":"534_CR70","unstructured":"Evaluating the effects of tradipitant vs. placebo in atopic dermatitis (EPIONE2). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04140695."},{"key":"534_CR71","doi-asserted-by":"publisher","first-page":"e030114","DOI":"10.1136\/bmjopen-2019-030114","volume":"10","author":"B Vincenzi","year":"2020","unstructured":"Vincenzi B, Trower M, Duggal A, et al. Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial. BMJ Open. 2020;10:e030114. https:\/\/doi.org\/10.1136\/bmjopen-2019-030114.","journal-title":"BMJ Open."},{"key":"534_CR72","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.mcna.2015.07.008","volume":"99","author":"R Fathi","year":"2015","unstructured":"Fathi R, Armstrong AW. The role of biologic therapies in dermatology. Med Clin N Am. 2015;99:1183\u201394.","journal-title":"Med Clin N Am."},{"key":"534_CR73","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-662-44605-8_9","volume":"226","author":"ER Storan","year":"2015","unstructured":"Storan ER, O\u2019Gorman SM, McDonald ID, Steinhoff M. Role of cytokines and chemokines in itch. Handb Exp Pharmacol. 2015;226:163\u201376. https:\/\/doi.org\/10.1007\/978-3-662-44605-8_9.","journal-title":"Handb Exp Pharmacol."},{"key":"534_CR74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","volume":"45","author":"JM Zhang","year":"2007","unstructured":"Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45:27\u201337. https:\/\/doi.org\/10.1097\/AIA.0b013e318034194e.","journal-title":"Int Anesthesiol Clin."},{"key":"534_CR75","first-page":"237","volume-title":"Itch: mechanisms and treatment","author":"F Cevikbas","year":"2014","unstructured":"Cevikbas F, Kempkes C, Buhl T, et al. Role of interleukin-31 and Oncostatin M in itch and neuroimmune communication. In: Carstens E, Akiyama T, editors. Itch: mechanisms and treatment. Boca Raton: CRC Press; 2014. p. 237\u201356."},{"key":"534_CR76","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","volume":"118","author":"MM Neis","year":"2006","unstructured":"Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118:930\u20137.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR77","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","volume":"133","author":"F Cevikbas","year":"2014","unstructured":"Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133:448\u201360.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR78","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","volume":"134","author":"JD Hamilton","year":"2014","unstructured":"Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293\u2013300.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130\u20139.","journal-title":"N Engl J Med."},{"key":"534_CR80","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","volume":"75","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016;75:506\u201315.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR81","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348.","journal-title":"N Engl J Med."},{"key":"534_CR82","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","volume":"94","author":"D Thaci","year":"2019","unstructured":"Thaci D, Simpson EL, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94:266\u201375.","journal-title":"J Dermatol Sci."},{"key":"534_CR83","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287\u2013303.","journal-title":"Lancet."},{"key":"534_CR84","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M De Bruin-Weller","year":"2018","unstructured":"De Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178:1083\u2013101.","journal-title":"Br J Dermatol."},{"issue":"1","key":"534_CR85","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336.","journal-title":"JAMA Dermatol."},{"key":"534_CR86","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82:377\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR87","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","volume":"82","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82:1328\u201336. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.060.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR88","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1001\/jamadermatol.2018.3912","volume":"155","author":"KM Beck","year":"2019","unstructured":"Beck KM, Yang EJ, Sekhon S, et al. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019;155:118\u201320.","journal-title":"JAMA Dermatol."},{"key":"534_CR89","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jdcr.2019.03.016","volume":"5","author":"PH Rambhia","year":"2019","unstructured":"Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep. 2019;5:471\u20133.","journal-title":"JAAD Case Rep."},{"key":"534_CR90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamadermatol.2018.3906","volume":"155","author":"NK Mollanazar","year":"2019","unstructured":"Mollanazar NK, Elgash M, Weaver L, et al. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol. 2019;155:121\u20132.","journal-title":"JAMA Dermatol."},{"key":"534_CR91","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2340\/00015555-3243","volume":"99","author":"ZZ Almustafa","year":"2019","unstructured":"Almustafa ZZ, Weller K, Autenrieth J, et al. Dupilumab in treatment of chronic prurigo: a case series and literature review. Acta Derm Venereol. 2019;99:905\u20136.","journal-title":"Acta Derm Venereol."},{"issue":"2","key":"534_CR92","doi-asserted-by":"publisher","first-page":"e13222","DOI":"10.1111\/dth.13222","volume":"33","author":"JG Holm","year":"2020","unstructured":"Holm JG, Agner T, Sand C, et al. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol Ther. 2020;33(2):e13222. https:\/\/doi.org\/10.1111\/dth.13222.","journal-title":"Dermatol Ther."},{"key":"534_CR93","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/jdv.15957","volume":"34","author":"A Calugareanu","year":"2020","unstructured":"Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34:e74\u20136. https:\/\/doi.org\/10.1111\/jdv.15957.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR94","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","volume":"154","author":"A Kaye","year":"2018","unstructured":"Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018;154:1225\u20136.","journal-title":"JAMA Dermatol."},{"key":"534_CR95","doi-asserted-by":"crossref","unstructured":"Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol Online J. 2019;25:13030\/qt25q9w6r9.","DOI":"10.5070\/D32511046147"},{"issue":"3","key":"534_CR96","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/medicines6030072","volume":"6","author":"LL Zhai","year":"2019","unstructured":"Zhai LL, Savage KT, Qiu CC, et al. Chronic pruritus responding to dupilumab\u2014a case series. Medicines (Basel). 2019;6(3):72. https:\/\/doi.org\/10.3390\/medicines6030072.","journal-title":"Medicines (Basel)."},{"key":"534_CR97","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jdcr.2019.01.024","volume":"5","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Brieva J. A successful case of dupilumab treatment for severe uremic pruritus. JAAD Case Rep. 2019;5:339\u201341.","journal-title":"JAAD Case Rep."},{"key":"534_CR98","unstructured":"Charite University. Cholinergic urticaria \u2013 efficacy of dupilumab (CHED). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03749148."},{"key":"534_CR99","unstructured":"Charite University. Dupilumab in chronic spontaneous urticaria (DUPICSU). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03749135."},{"key":"534_CR100","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78:863\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.017.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"534_CR101","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411\u201320. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0079.","journal-title":"JAMA Dermatol."},{"key":"534_CR102","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1476-5381.2011.01659.x","volume":"166","author":"RD May","year":"2012","unstructured":"May RD, Monk PD, Cohen ES, et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol. 2012;166:177\u201393.","journal-title":"Br J Pharmacol."},{"key":"534_CR103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143:135\u201341.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR104","unstructured":"LEO Pharma. Drug\u2013drug interaction trial with tralokinumab in moderate to severe atopic dermatitis \u2013 ECZTRA 4. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03556592."},{"key":"534_CR105","unstructured":"LEO Pharma. Tralokinumab in combination with topical corticosteroids in subjects with severe atopic dermatitis who are not adequately controlled with or have contraindications to oral cyclosporine A (ECZTRA 7). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03761537."},{"key":"534_CR106","unstructured":"LEO Pharma. Tralokinumab monotherapy for adolescent subjects with moderate to severe atopic dermatitis\u2014ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03526861."},{"key":"534_CR107","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2133.2012.11099.x","volume":"167","author":"G Girolomoni","year":"2012","unstructured":"Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717\u201324.","journal-title":"Br J Dermatol."},{"key":"534_CR108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133\u201342.","journal-title":"Immunology."},{"key":"534_CR109","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","volume":"38","author":"N Amatya","year":"2017","unstructured":"Amatya N, Garg AV, Gaffen SL. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 2017;38:310\u201322.","journal-title":"Trends Immunol."},{"key":"534_CR110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","volume":"133","author":"DA Martin","year":"2013","unstructured":"Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Investig Dermatol. 2013;133:17\u201326.","journal-title":"J Investig Dermatol."},{"key":"534_CR111","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338.","journal-title":"N Engl J Med."},{"key":"534_CR112","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Thaci","year":"2015","unstructured":"Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR113","unstructured":"GWT-TUD GmbH. Investigation of efficacy of secukinumab in patients with moderate to severe atopic dermatitis (Secu_-in_AD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03568136."},{"key":"534_CR114","unstructured":"Icahn School of Medicine at Mount Sinai. Secukinumab for treatment of atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT02594098."},{"key":"534_CR115","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350. https:\/\/doi.org\/10.2147\/JIR.S100940.","journal-title":"J Inflamm Res."},{"key":"534_CR116","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s13555-018-0267-9","volume":"8","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Reich A, Steinhoff M, et al. Impact of ixekizumab treatment on itch and psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis: an integrated analysis of two phase III randomized studies. Dermatol Ther (Heidelb). 2018;8:621\u201337.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"534_CR117","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.16736","volume":"179","author":"C Ryan","year":"2018","unstructured":"Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018;179:844\u201352. https:\/\/doi.org\/10.1111\/bjd.16736.","journal-title":"Br J Dermatol."},{"key":"534_CR118","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.jsxm.2018.09.004","volume":"15","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Foley P, Ryan C, et al. Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, double-blind study. J Sex Med. 2018;15:1645\u201352. https:\/\/doi.org\/10.1016\/j.jsxm.2018.09.004.","journal-title":"J Sex Med."},{"key":"534_CR119","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181\u20139.","journal-title":"N Engl J Med."},{"key":"534_CR120","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jdv.14913","volume":"32","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018;32:1305\u201313.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR121","doi-asserted-by":"publisher","unstructured":"Di Meglio P, Nestle FO. The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep. 2010;2:40. https:\/\/doi.org\/10.3410\/b2-40.","DOI":"10.3410\/b2-40"},{"key":"534_CR122","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","volume":"129","author":"A Di Cesare","year":"2009","unstructured":"Di Cesare A, Di Meglio P, Nestle FO. The IL-23\/Th17 axis in the immunopathogenesis of psoriasis. J Investig Dermatol. 2009;129:1339\u201350.","journal-title":"J Investig Dermatol."},{"key":"534_CR123","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"K Reich","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177:1014\u201323.","journal-title":"Br J Dermatol."},{"key":"534_CR124","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","volume":"376","author":"KA Papp","year":"2017","unstructured":"Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551\u201360.","journal-title":"N Engl J Med."},{"key":"534_CR125","doi-asserted-by":"publisher","first-page":"212594","DOI":"10.7573\/dic.212594","volume":"8","author":"M Nogueira","year":"2019","unstructured":"Nogueira M, Torres T. Guselkumab for the treatment of psoriasis\u2014evidence to date. Drugs Context. 2019;8:212594. https:\/\/doi.org\/10.7573\/dic.212594.","journal-title":"Drugs Context."},{"key":"534_CR126","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405\u201317.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR127","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418\u201331.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178:114\u201323.","journal-title":"Br J Dermatol."},{"key":"534_CR129","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/jdv.14910","volume":"32","author":"KA Papp","year":"2018","unstructured":"Papp KA, Blauvelt A, Kimball AB, et al. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. J Eur Acad Dermatol Venereol. 2018;32:1515\u201322.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR130","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Tha\u00e7i D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173:930\u20139.","journal-title":"Br J Dermatol."},{"key":"534_CR131","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp K, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276\u201388.","journal-title":"Lancet."},{"key":"534_CR132","unstructured":"Sun Pharma Global FZE. A real world study evaluating the long-term quality of life of tildrakizumab in adult patients with psoriasis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03718299."},{"key":"534_CR133","unstructured":"Almirall, S.A. Efficacy and safety of tildrakizumab in participants with moderate-to-severe chronic plaque psoriasis who are non-responders to dimethyl fumarate therapy (TRANSITION). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04263610."},{"key":"534_CR134","unstructured":"Almirall, S.A. Observational study of tildrakizumab in patients with moderate to severe plaque psoriasis in routine clinical practice (SAIL). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04203693."},{"key":"534_CR135","unstructured":"Almirall, S.A. Efficacy and safety of tildrakizumab 100 milligrams (mg) in participants with moderate\u2013severe chronic plaque psoriasis and its impact on their quality of life (TRIBUTE). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04229836."},{"key":"534_CR136","unstructured":"Sun Pharma Global FZE. Efficacy and safety of tildrakizumab in the treatment of scalp psoriasi. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03897088."},{"key":"534_CR137","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/all.12316","volume":"69","author":"T Hawro","year":"2014","unstructured":"Hawro T, Saluja R, Weller K, et al. Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy. 2014;69:113\u20137.","journal-title":"Allergy."},{"key":"534_CR138","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","volume":"141","author":"IS Bagci","year":"2018","unstructured":"Bagci IS, Ruzicka T. IL-31: a new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141:858\u201366.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR139","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 2017;376:826\u201335.","journal-title":"N Engl J Med."},{"key":"534_CR140","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S Stander","year":"2020","unstructured":"Stander S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382:706\u201316.","journal-title":"N Engl J Med."},{"key":"534_CR141","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.jid.2019.03.636","volume":"139","author":"Z Mikhak","year":"2019","unstructured":"Mikhak Z, Bissonnette R, Siri D, et al. KPL-716, anti-Oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis. J Investig Dermatol. 2019;139:S96. https:\/\/doi.org\/10.1016\/j.jid.2019.03.636.","journal-title":"J Investig Dermatol."},{"key":"534_CR142","unstructured":"Kiniksa Pharmaceuticals Ltd. A study to assess the efficacy, safety and tolerability of KPL-716 in reducing pruritus in chronic pruritic diseases. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03858634."},{"key":"534_CR143","unstructured":"Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint. https:\/\/www.kiniksa.com\/wp-content\/uploads\/2020\/04\/KPL716.PN_.P2a.PR_.Final_.pdf."},{"key":"534_CR144","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","volume":"44","author":"JP Arm","year":"2014","unstructured":"Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44:1371\u201385.","journal-title":"Clin Exp Allergy."},{"key":"534_CR145","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","volume":"381","author":"M Maurer","year":"2019","unstructured":"Maurer M, Gim\u00e9nez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381:1321\u201332.","journal-title":"N Engl J Med"},{"key":"534_CR146","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med."},{"key":"534_CR147","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","volume":"76","author":"R Shreberk-Hassidim","year":"2017","unstructured":"Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76:745\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.004.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR148","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736\u201344.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR149","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","volume":"82","author":"BS Kim","year":"2020","unstructured":"Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82:1305\u201313. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.009.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR150","unstructured":"Incyte Corporation. TRuE AD2\u2014an efficacy and safety study of ruxolitinib cream in adolescents and adults with atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03745651."},{"key":"534_CR151","unstructured":"Incyte Corporation. TRuE AD1\u2014an efficacy and safety study of ruxolitinib cream in adolescents and adults with atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03745638."},{"key":"534_CR152","unstructured":"Incyte Corporation. A pharmacokinetic study of ruxolitinib phosphate cream in pediatric subjects with atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03257644."},{"key":"534_CR153","unstructured":"Aaron R. Mangold. Topical ruxolitinib lichen planus. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03697460."},{"key":"534_CR154","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Topical ruxolitinib for cutaneous chronic graft versus host disease (cGvHD). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03395340."},{"key":"534_CR155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335.","journal-title":"N Engl J Med."},{"key":"534_CR156","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","volume":"130","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017;130:1768\u201371.","journal-title":"Blood."},{"key":"534_CR157","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00277-016-2674-2","volume":"95","author":"BE Vaa","year":"2016","unstructured":"Vaa BE, Tefferi A, Gangat N, et al. Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors. Ann Hematol. 2016;95:1185\u20139.","journal-title":"Ann Hematol."},{"key":"534_CR158","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020. https:\/\/doi.org\/10.1111\/bjd.18898.","journal-title":"Br J Dermatol"},{"key":"534_CR159","unstructured":"Eli Lilly and Company. A study of baricitinib (LY3009104) in adult participants with moderate to severe atopic dermatitis (BREEZE-AD5). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03435081."},{"key":"534_CR160","unstructured":"Eli Lilly and Company. A study of long-term baricitinib (LY3009104) therapy in atopic dermatitis (BREEZE-AD3). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03334435."},{"key":"534_CR161","unstructured":"Eli Lilly and Company. A study of baricitinib (LY3009104) in participants with moderate to severe atopic dermatitis (BREEZE-AD6). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03559270."},{"key":"534_CR162","unstructured":"Eli Lilly and Company. A study of baricitinib (LY3009104) in children and adolescents with atopic dermatitis (BREEZE-AD-PEDS). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03952559."},{"key":"534_CR163","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80:913\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.018.","journal-title":"J Am Acad Dermatol"},{"key":"534_CR164","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","volume":"174","author":"KA Papp","year":"2016","unstructured":"Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174:1266\u201376.","journal-title":"Br J Dermatol."},{"key":"534_CR165","first-page":"318","volume":"34","author":"JA Hodge","year":"2016","unstructured":"Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib\u2014an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318\u201328.","journal-title":"Clin Exp Rheumatol."},{"key":"534_CR166","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09546634.2013.861891","volume":"26","author":"AG Bushmakin","year":"2015","unstructured":"Bushmakin AG, Mamolo C, Cappelleri JC, et al. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatol Treat. 2015;26:19\u201322.","journal-title":"J Dermatol Treat."},{"issue":"1162\u201370","key":"534_CR167","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jaad.2016.07.040","volume":"75","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Tha\u00e7i D, Gooderham M, et al. Tofacitinib improves pruritus and health-related quality of life up to 52\u00a0weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1162\u201370):e3. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.040.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR168","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74:841\u201350.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR169","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","volume":"30","author":"F Valenzuela","year":"2016","unstructured":"Valenzuela F, Paul C, Mallbris L, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol. 2016;30:1753\u20139.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jdv.13808","volume":"31","author":"CE Griffiths","year":"2017","unstructured":"Griffiths CE, Vender R, Sofen H, et al. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:323\u201332.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR171","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2340\/00015555-2856","volume":"98","author":"S St\u00e4nder","year":"2018","unstructured":"St\u00e4nder S, Luger T, Cappelleri JC, et al. Validation of the Itch severity item as a measurement tool for pruritus in patients with psoriasis: results from a phase 3 tofacitinib program. Acta Derm Venereol. 2018;98:340\u20135.","journal-title":"Acta Derm Venereol."},{"key":"534_CR172","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2804","author":"F Wang","year":"2019","unstructured":"Wang F, Morris C, Bodet ND, et al. Treatment of refractory chronic pruritus of unknown origin with tofacitinib in patients with rheumatoid arthritis. JAMA Dermatol. 2019. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2804.","journal-title":"JAMA Dermatol"},{"key":"534_CR173","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902\u201311.","journal-title":"Br J Dermatol."},{"key":"534_CR174","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","volume":"16","author":"KA Papp","year":"2016","unstructured":"Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016;16:15. https:\/\/doi.org\/10.1186\/s12895-016-0051-4.","journal-title":"BMC Dermatol."},{"key":"534_CR175","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855.","journal-title":"JAMA Dermatol."},{"key":"534_CR176","unstructured":"Pfizer. Study to evaluate efficacy and safety of PF-04965842 in subjects aged 12\u00a0years and older with moderate to severe atopic dermatitis (JADE Mono-1). ClinicalTrial.gov. https:\/\/clinicaltrials.gov\/show\/NCT03349060."},{"key":"534_CR177","unstructured":"Pfizer. Study evaluating efficacy and safety of PF-04965842 in subjects aged 12\u00a0years and older with moderate to severe atopic dermatitis (JADE Mono-2). ClinicalTrial.gov. https:\/\/clinicaltrials.gov\/show\/NCT03575871."},{"key":"534_CR178","unstructured":"Pfizer. Study evaluating efficacy and safety of PF-04965842 and dupilumab in adult subjects with moderate to severe atopic dermatitis on background topical therapy (JADE Compare). ClinicalTrial.gov. https:\/\/clinicaltrials.gov\/show\/NCT03720470."},{"key":"534_CR179","unstructured":"Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis. https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2020\/Pfizer-Announces-Positive-Top-Line-Results-from-Third-Phase-3-Trial-of-Abrocitinib-for-Moderate-to-Severe-Atopic-Dermatitis-Which-Showed-Improvements-in-Skin-Clearance-Disease-Extent-and-Severity-and-Itch\/default.aspx."},{"key":"534_CR180","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. https:\/\/doi.org\/10.1186\/s41927-018-0031-x.","journal-title":"BMC Rheumatol."},{"key":"534_CR181","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145:877\u201384.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR182","unstructured":"AbbVie. A study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis (Measure Up 2). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03607422."},{"key":"534_CR183","unstructured":"AbbVie. Evaluation of upadacitinib in adolescent and adult patients with moderate to severe atopic dermatitis (eczema) (Measure Up 1). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03569293."},{"key":"534_CR184","unstructured":"AbbVie. A study to evaluate upadacitinib in combination with topical corticosteroids in adolescent and adult participants with moderate to severe atopic dermatitis (AD Up). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03568318."},{"key":"534_CR185","unstructured":"AbbVie. A study to compare safety and efficacy of upadacitinib to dupilumab in adult participants with moderate to severe atopic dermatitis (Heads Up). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03738397."},{"key":"534_CR186","unstructured":"AbbVie. A study to evaluate the pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with severe atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03646604."},{"key":"534_CR187","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41\u201351.","journal-title":"Inflamm Res."},{"key":"534_CR188","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","volume":"182","author":"M Worm","year":"2020","unstructured":"Worm M, Bauer A, Elsner P, et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2020;182:1103\u201310.","journal-title":"Br J Dermatol."},{"key":"534_CR189","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","volume":"82","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82:823\u201331.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR190","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","volume":"144","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144:1575\u201383.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR191","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/1346-8138.15173","volume":"47","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47:114\u201320.","journal-title":"J Dermatol."},{"key":"534_CR192","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/exd.13808","volume":"28","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28:3\u201310. https:\/\/doi.org\/10.1111\/exd.13808.","journal-title":"Exp Dermatol."},{"key":"534_CR193","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/pde.12780","volume":"33","author":"WL Tom","year":"2016","unstructured":"Tom WL, Van Syoc M, Chanda S, et al. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol. 2016;33:150\u20139. https:\/\/doi.org\/10.1111\/pde.12780.","journal-title":"Pediatr Dermatol"},{"issue":"494\u2013503","key":"534_CR194","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(494\u2013503):e6. https:\/\/doi.org\/10.1016\/j.jaad.2016.05.046.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR195","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2340\/00015555-2893","volume":"98","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Gold LF, Lebwohl MG, et al. Early Relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018;98:484\u20139.","journal-title":"Acta Derm Venereol."},{"key":"534_CR196","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12906-019-2709-z","volume":"19","author":"Y Zhong","year":"2019","unstructured":"Zhong Y, Xu H, Zhong Y, et al. Identification and characterization of the Cucurbitacins, a novel class of small-molecule inhibitors of Tropomyosin receptor kinase A. BMC Complement Altern Med. 2019;19:295. https:\/\/doi.org\/10.1186\/s12906-019-2709-z.","journal-title":"BMC Complement Altern Med."},{"key":"534_CR197","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2340\/00015555-2047","volume":"95","author":"D Roblin","year":"2015","unstructured":"Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95:542\u20138.","journal-title":"Acta Derm Venereol"},{"key":"534_CR198","unstructured":"Duffin KC, St\u00e4nder S, Draelos Z, et al. SNA-120, a novel topical non-steroidal therapy for psoriasis and associated pruritus that targets the NGF\/TrkA pathway: results from a multicentre phase 2b study. 10th World Congress of Itch. 17\u201319 November 2019; Sydney, NSW. OP15."},{"key":"534_CR199","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/archinte.1972.03650040156014","volume":"130","author":"JH Herndon Jr","year":"1972","unstructured":"Herndon JH Jr. Pathophysiology of pruritus associated with elevated bile acid levels in serum. Arch Intern Med. 1972;130:632\u20137.","journal-title":"Arch Intern Med."},{"key":"534_CR200","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0016-5085(19)31870-0","volume":"73","author":"CN Ghent","year":"1977","unstructured":"Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology. 1977;73:1125\u201330.","journal-title":"Gastroenterology."},{"key":"534_CR201","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199405263302117","volume":"330","author":"M Raderer","year":"1994","unstructured":"Raderer M, M\u00fcller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med. 1994;330:1540.","journal-title":"N Engl J Med."},{"key":"534_CR202","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","volume":"139","author":"AE Kremer","year":"2010","unstructured":"Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008\u201318.","journal-title":"Gastroenterology."},{"key":"534_CR203","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep4.1244","volume":"2","author":"BL Shneider","year":"2018","unstructured":"Shneider BL, Spino C, Kamath BM, et al. Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in alagille syndrome. Hepatol Commun. 2018;2:1184\u201398.","journal-title":"Hepatol Commun."},{"key":"534_CR204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","volume":"3","author":"MJ Mayo","year":"2019","unstructured":"Mayo MJ, Pockros PJ, Jones D, et al. A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 2019;3:365\u201381.","journal-title":"Hepatol Commun."},{"key":"534_CR205","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","volume":"389","author":"VS Hegade","year":"2017","unstructured":"Hegade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017;389:1114\u201323.","journal-title":"Lancet."},{"key":"534_CR206","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","volume":"8","author":"S Al-Dury","year":"2018","unstructured":"Al-Dury S, Wahlstr\u00f6m A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8:6658. https:\/\/doi.org\/10.1038\/s41598-018-25214-0.","journal-title":"Sci Rep."},{"key":"534_CR207","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mehy.2018.05.001","volume":"116","author":"M Napolitano","year":"2018","unstructured":"Napolitano M, Patruno C. Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin disease. Med Hypotheses. 2018;116:96\u2013100.","journal-title":"Med Hypotheses."},{"key":"534_CR208","doi-asserted-by":"publisher","first-page":"E5424","DOI":"10.3390\/ijms20215424","volume":"20","author":"M Furue","year":"2019","unstructured":"Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20:E5424. https:\/\/doi.org\/10.3390\/ijms20215424.","journal-title":"Int J Mol Sci."},{"key":"534_CR209","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00281-013-0394-4","volume":"35","author":"C Esser","year":"2013","unstructured":"Esser C, Bargen I, Weighardt H, et al. Functions of the aryl hydrocarbon receptor in the skin. Semin Immunopathol. 2013;35:677\u201391.","journal-title":"Semin Immunopathol."},{"key":"534_CR210","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.jid.2016.06.627","volume":"136","author":"K Haas","year":"2016","unstructured":"Haas K, Weighardt H, Deenen R, et al. Aryl hydrocarbon receptor in keratinocytes is essential for murine skin barrier integrity. J Investig Dermatol. 2016;136:2260\u20139.","journal-title":"J Investig Dermatol."},{"key":"534_CR211","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Investig Dermatol. 2017;137:2110\u20139.","journal-title":"J Investig Dermatol."},{"key":"534_CR212","doi-asserted-by":"publisher","first-page":"E6005","DOI":"10.3390\/ijms20236005","volume":"20","author":"C Vogeley","year":"2019","unstructured":"Vogeley C, Esser C, T\u00fcting T, et al. Role of the aryl hydrocarbon receptor in environmentally induced skin aging and skin carcinogenesis. Int J Mol Sci. 2019;20:E6005. https:\/\/doi.org\/10.3390\/ijms20236005.","journal-title":"Int J Mol Sci."},{"issue":"89\u201398","key":"534_CR213","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jaad.2018.06.047","volume":"80","author":"J Peppers","year":"2019","unstructured":"Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(89\u201398):e3. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.047.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR214","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1744-8069-4-29","volume":"4","author":"WS Shim","year":"2008","unstructured":"Shim WS, Oh U. Histamine-induced itch and its relationship with pain. Mol Pain. 2008;4:29. https:\/\/doi.org\/10.1186\/1744-8069-4-29.","journal-title":"Mol Pain."},{"key":"534_CR215","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2332\/allergolint.13-RA-0675","volume":"63","author":"Y Ohsawa","year":"2014","unstructured":"Ohsawa Y, Hirasawa N. The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergol Int. 2014;63:533\u201342.","journal-title":"Allergol Int."},{"key":"534_CR216","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaci.2008.12.1110","volume":"123","author":"R Gutzmer","year":"2009","unstructured":"Gutzmer R, Mommert S, Gschwandtner M, et al. The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol. 2009;123:619\u201325.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR217","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaci.2006.08.034","volume":"119","author":"PJ Dunford","year":"2007","unstructured":"Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol. 2007;119:176\u201383.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR218","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/jid.2009.358","volume":"130","author":"JM Cowden","year":"2010","unstructured":"Cowden JM, Zhang M, Dunford PJ, et al. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Investig Dermatol. 2010;130:1023\u201333.","journal-title":"J Investig Dermatol."},{"key":"534_CR219","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","volume":"42","author":"Y Murata","year":"2015","unstructured":"Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015;42:129\u201339.","journal-title":"J Dermatol."},{"issue":"1830\u20131837","key":"534_CR220","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.jaci.2018.07.047","volume":"143","author":"T Werfel","year":"2019","unstructured":"Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1830\u20131837):e4. https:\/\/doi.org\/10.1016\/j.jaci.2018.07.047.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR221","unstructured":"Novartis Pharmaceuticals. A study to assess the safety and efficacy of ZPL389 in patients with moderate to severe atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03517566."},{"key":"534_CR222","unstructured":"Novartis Pharmaceuticals. A study to assess the safety and efficacy of ZPL389 with TCS\/TCI in atopic dermatitis patients (ZESTExt). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03948334."},{"key":"534_CR223","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5114\/ada.2020.93381","volume":"37","author":"GS Pancar","year":"2020","unstructured":"Pancar GS, Kalkan G, Eyupoglu O. The effects of 755\u00a0nm alexandrite laser on skin dryness and pruritus. Adv Dermatol Allergol. 2020;37:29\u201333.","journal-title":"Adv Dermatol Allergol."},{"key":"534_CR224","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaad.2017.08.001","volume":"78","author":"E Boozalis","year":"2018","unstructured":"Boozalis E, Sheu M, Selph J, et al. Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus. J Am Acad Dermatol. 2018;78:192\u20134.","journal-title":"J Am Acad Dermatol."},{"key":"534_CR225","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/cercor\/bhs363","volume":"24","author":"V Napadow","year":"2014","unstructured":"Napadow V, Li A, Loggia ML, et al. The brain circuitry mediating antipruritic effects of acupuncture. Cereb Cortex. 2014;24:873\u201382.","journal-title":"Cereb Cortex."},{"key":"534_CR226","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fnins.2019.00215","volume":"13","author":"S Min","year":"2019","unstructured":"Min S, Kim KW, Jung WM, et al. Acupuncture for histamine-induced itch: association with increased parasympathetic tone and connectivity of putamen-midcingulate cortex. Front Neurosci. 2019;13:215. https:\/\/doi.org\/10.3389\/fnins.2019.00215.","journal-title":"Front Neurosci."},{"key":"534_CR227","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/exd.13803","volume":"28","author":"O Jones","year":"2019","unstructured":"Jones O, Schindler I, Holle H. Transcranial magnetic stimulation over contralateral primary somatosensory cortex disrupts perception of itch intensity. Exp Dermatol. 2019;28:1380\u20134. https:\/\/doi.org\/10.1111\/exd.13803.","journal-title":"Exp Dermatol."},{"key":"534_CR228","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.burns.2019.02.007","volume":"45","author":"AF Samhan","year":"2019","unstructured":"Samhan AF, Abdelhalim NM. Impacts of low-energy extracorporeal shockwave therapy on pain, pruritus, and health-related quality of life in patients with burn: a randomized placebo-controlled study. Burns. 2019;45:1094\u2013101.","journal-title":"Burns."},{"key":"534_CR229","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ctim.2019.06.015","volume":"45","author":"A Khorsand","year":"2019","unstructured":"Khorsand A, Salari R, Noras MR, et al. The effect of massage and topical violet oil on the severity of pruritus and dry skin in hemodialysis patients: a randomized controlled trial. Complement Ther Med. 2019;45:248\u201353.","journal-title":"Complement Ther Med."},{"key":"534_CR230","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fpsyt.2019.00436","volume":"10","author":"SH Meeuwis","year":"2019","unstructured":"Meeuwis SH, van Middendorp H, van Laarhoven AIM, et al. Effects of open- and closed-label nocebo and placebo suggestions on itch and itch expectations. Front Psychiatry. 2019;10:436. https:\/\/doi.org\/10.3389\/fpsyt.2019.00436.","journal-title":"Front Psychiatry."},{"key":"534_CR231","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16149","author":"S Demirtas","year":"2019","unstructured":"Demirtas S, Houssais C, Tanniou J, et al. Effectiveness of a music intervention on pruritus: an open randomized prospective study. J Eur Acad Dermatol Venereol. 2019. https:\/\/doi.org\/10.1111\/jdv.16149.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"534_CR232","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1038\/s41467-018-05709-0","volume":"9","author":"WT Ralvenius","year":"2018","unstructured":"Ralvenius WT, Neumann E, Pagani M, et al. Itch suppression in mice and dogs by modulation of spinal \u03b12 and \u03b13GABAA receptors. Nat Commun. 2018;9:3230. https:\/\/doi.org\/10.1038\/s41467-018-05709-0.","journal-title":"Nat Commun."},{"key":"534_CR233","doi-asserted-by":"publisher","first-page":"10888","DOI":"10.1038\/s41598-019-47267-5","volume":"9","author":"B Sanjel","year":"2019","unstructured":"Sanjel B, Maeng HJ, Shim WS. BAM8-22 and its receptor MRGPRX1 may attribute to cholestatic pruritus. Sci Rep. 2019;9:10888. https:\/\/doi.org\/10.1038\/s41598-019-47267-5.","journal-title":"Sci Rep."},{"key":"534_CR234","doi-asserted-by":"publisher","first-page":"e48431","DOI":"10.7554\/eLife.48431","volume":"8","author":"H Yu","year":"2019","unstructured":"Yu H, Zhao T, Liu S, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. Elife. 2019;8:e48431. https:\/\/doi.org\/10.7554\/eLife.48431.","journal-title":"Elife."},{"key":"534_CR235","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1172\/JCI122481","volume":"128","author":"J Salvatierra","year":"2018","unstructured":"Salvatierra J, Diaz-Bustamante M, Meixiong J, et al. A disease mutation reveals a role for NaV1.9 in acute itch. J Clin Investig. 2018;128:5434\u201347.","journal-title":"J Clin Investig."},{"key":"534_CR236","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/s41598-020-59092-2","volume":"10","author":"H K\u00fchn","year":"2020","unstructured":"K\u00fchn H, Kappes L, Wolf K, et al. Complementary roles of murine NaV1.7, NaV1.8 and NaV1.9 in acute itch signalling. Sci Rep. 2020;10:2326. https:\/\/doi.org\/10.1038\/s41598-020-59092-2.","journal-title":"Sci Rep."},{"key":"534_CR237","doi-asserted-by":"publisher","unstructured":"Solinski HJ, Dranchak P, Oliphant E, et al. Inhibition of natriuretic peptide receptor 1 reduces itch in mice. Sci Transl Med. 2019;11:eaav5464. https:\/\/doi.org\/10.1126\/scitranslmed.aav5464.","DOI":"10.1126\/scitranslmed.aav5464"},{"key":"534_CR238","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bph.14952","volume":"177","author":"J Meng","year":"2020","unstructured":"Meng J, Chen W, Wang J. Interventions in the B-type natriuretic peptide signalling pathway as a means of controlling chronic itch. Br J Pharmacol. 2020;177:1025\u201340.","journal-title":"Br J Pharmacol."},{"key":"534_CR239","doi-asserted-by":"crossref","first-page":"992","DOI":"10.2174\/1871520619666190408133141","volume":"19","author":"MJ Yu","year":"2019","unstructured":"Yu MJ, Yao S, Li TT, et al. Dual anti-cancer and anti-itch activity of PD176252 analogues: design, synthesis and biological evaluation. Anticancer Agents Med Chem. 2019;19:992\u20131001.","journal-title":"Anticancer Agents Med Chem."},{"key":"534_CR240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuroscience.2019.12.048","volume":"429","author":"Z Huang","year":"2020","unstructured":"Huang Z, Zhou X, Zhang J, et al. Bulleyaconitine A inhibits itch and itch sensitization induced by histamine and chloroquine. Neuroscience. 2020;429:68\u201377.","journal-title":"Neuroscience."},{"key":"534_CR241","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jid.2018.08.019","volume":"139","author":"TP Barr","year":"2019","unstructured":"Barr TP, Garzia C, Guha S, et al. PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models. J Investig Dermatol. 2019;139:412\u201321.","journal-title":"J Investig Dermatol."},{"key":"534_CR242","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.bbi.2019.04.026","volume":"80","author":"H Jiang","year":"2019","unstructured":"Jiang H, Cui H, Wang T, et al. CCL2\/CCR2 signaling elicits itch- and pain-like behavior in a murine model of allergic contact dermatitis. Brain Behav Immun. 2019;80:464\u201373.","journal-title":"Brain Behav Immun."},{"issue":"8","key":"534_CR243","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/09546634.2017.1329502","volume":"28","author":"SR Feldman","year":"2017","unstructured":"Feldman SR, Green L, Kimball AB, et al. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatol Treat. 2017;28(8):716\u201321.","journal-title":"J Dermatol Treat."},{"key":"534_CR244","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2340\/00015555-3195","volume":"99","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Soung J, Weiss J, et al. Secukinumab provides rapid relief from itching and pain in patients with moderate-to-severe psoriasis: patient symptom diary data from two phase 3, randomized, placebo-controlled clinical trials. Acta Derm Venereol. 2019;99:820\u20131.","journal-title":"Acta Derm Venereol."},{"key":"534_CR245","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190\u20139.","journal-title":"N Engl J Med."},{"key":"534_CR246","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541\u201351.","journal-title":"Lancet."},{"issue":"6","key":"534_CR247","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348\u201358. https:\/\/doi.org\/10.1111\/bjd.18851.","journal-title":"Br J Dermatol"},{"key":"534_CR248","unstructured":"AbbVie. A study to evaluate risankizumab in adult and adolescent subjects with moderate to severe atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03706040."},{"key":"534_CR249","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18696","author":"D Tha\u04abi","year":"2019","unstructured":"Tha\u04abi D, Pinter A, Sebastian M, et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18696.","journal-title":"Br J Dermatol"},{"key":"534_CR250","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"O Nemoto","year":"2016","unstructured":"Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174:296\u2013304.","journal-title":"Br J Dermatol."},{"issue":"1121\u20131130","key":"534_CR251","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jaci.2018.03.018","volume":"142","author":"K Kabashima","year":"2018","unstructured":"Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(1121\u20131130):e7. https:\/\/doi.org\/10.1016\/j.jaci.2018.03.018.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR252","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","volume":"145","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145:173\u201382.","journal-title":"J Allergy Clin Immunol."},{"key":"534_CR253","unstructured":"Galderma R&D. Long-term safety and efficacy of nemolizumab with moderate-to-severe atopic dermatitis. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT03989206."},{"key":"534_CR254","unstructured":"Galderma R&D. A long-term study of nemolizumab (CD14152) in participants with prurigo nodularis (PN). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/show\/NCT04204616."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00534-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T23:47:01Z","timestamp":1625010421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00534-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":254,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00534-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"30 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to assist in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jacek C. Szepietowski reports personal fees from Abbvie, Leo Pharma, Novartis, Pierre-Fabre, Menlo Therapeutics, Sienna Biopharmaceuticals, Trevi, Janssen, Sunfarm, Elli-Lilly, Berlin-Chemie Mennarini, Merck, Regeneron, Sanofi-Genzyme, Amgen, Boehringer Ingelheim, Galapagos, InflaRX, Pfizer, UCB, Incyte and Helm. Radomir Reszke and Piotr Krajewski have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}